


**CB-10,
A Novel Class IO therapeutic Antibody Targeting
Tumor-Specific Immune Suppression In Broad Cancers**

- **An outpatient infusable drug**
- **Infusion every 3-4 weeks**
- **No side effects**

CB-10 Development Milestone and Fund Needed



Complete the Manufacturing Sufficient Clinical Drug so that we can treat more people!

Social and Economical Impact


Social Impact

CB-10 could fulfill the large global unmet need for cancer treatment, prolong many millions of lives

Economic Impact

- Counting all cancer patients, only a small population (12.5%) of ALL cancer patients can benefit from current IO drugs; but the Global IO drug market is about \$138.87Bn in 2024, projected \$224.30Bn by 2030, 8.3% CAGR
- CB-10 can not only capture all the IO drug failures but also makes current IO drugs work better.
- CB-10 capture even 25% of the Global Cancer Market, ~\$276Bn annual revenue

Benefit (12.5%)
2024 Market: \$138.87Bn
2030 Market: \$224.50Bn




NOT Benefit,
Unmet need
87.5%

All Cancers


CB-10 Indications: Cross-board metastatic cancer types

CB-10 target MIC expression (**brown staining**),
only tumor, not normal tissue – safety feature

TUMOR



NORMAL TISSUE (None)






How Does CB-10 Work?

Cancer Cell:
Produce sMIC
to suppress immunity

CB-10:
Captures and
transforms sMIC from
Immune suppression
to immune activation

OUTCOME:
Immune Revamping
Tumor Elimination



- Immune dysfunction
- Tumor metastasis
- Not response to current immunotherapy



NK and CD8 T cell activation
Tumor elimination

Also enhances the efficacy
of current IO drugs


CB-10 Single Agent: Eradicate tumors and Prevents Tumor Recurrence

- ◆ Effective with low dose (1 mg/Kg) and outperform competitor

Competitor
(inhibiting sMIC production)




- ◆ Long lasting cure and prevent tumor re-growth




CB-10 Single Agent: eliminate systemic metastatic tumors (novel bladder tumor model)


Carcinogen (Agent Orange)
-induced **bladder tumor**
(spread to multiple organs)



2 wks CB-10 therapy



4 wks CB-10 therapy



Impact and Revenue Forecast



Invest 1.5-2.0M to help produce sufficient drugs for clinical testing

Social Impact

CB-10 could fulfill the large Global unmet need for cancer patients, prolong lives

Economic Impact

- Approved IO drugs with ONLY a small population (8%) of patients can benefit, but the Global IO market is about \$138.87Bn in 2024, projected \$224.30Bn by 2030, 8.3% CAGR
- CB-10 can not only capture all the IO drug failures but also makes current IO drugs work better.
- CB-10 captures even 10% of the Global Cancer Market, ~\$140Bn annual revenue

Early-stage revenue stream (based on 2023 data)

Total (\$Bn)

- At Phase I clinic out-licensing: > \$2 Bn
- At Phase II clinic out-licensing \$2.8-22 Bn

(source: www.nature.com/biopharmdeal | December 2023 | B45)